Tirzepatide Dosing Schedule (2026): Week-by-Week

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

The tirzepatide dosing schedule is one of those topics where the official chart is simple, but the practical questions are not. Standard FDA-approved tirzepatide titration moves through six weekly dose levels — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg — with at least four weeks between each step. That schedule applies to Zepbound (weight management) and Mounjaro (type 2 diabetes), and it is the schedule the PlexusDx Tirzepatide Injection Protocol follows for compounded tirzepatide. What the chart does not tell you: how to handle a missed dose, whether a slower titration fits your biology, what an oral tirzepatide schedule looks like instead, and how a single genetic variant (GIPR rs1800437) can shift the right titration pace before week one. This guide walks through the week-by-week schedule for both injection and oral formats, the milligram-to-unit conversions that keep compounded patients safe, and the personalization points the standard population-average schedule does not address.

The Standard FDA Tirzepatide Dosing Schedule (Week-by-Week)

The FDA-approved tirzepatide titration schedule for both Zepbound and Mounjaro is identical. You start at 2.5mg once weekly for four weeks (initiation only — not a maintenance dose), then step up to 5mg once weekly for four weeks. From there, your provider may increase the dose by 2.5mg every four or more weeks based on response and tolerability, moving through 7.5mg, 10mg, 12.5mg, and finally 15mg, which is the maximum approved weekly dose for adults. Many patients settle at 5mg or 10mg as their long-term maintenance dose — reaching 15mg is not the goal. The goal is the lowest dose that produces clinically meaningful weight loss while remaining tolerable. The PlexusDx Tirzepatide Injection Protocol mirrors this exact six-step titration ladder ($249/mo across all six dose levels), and the prescribing clinician can hold you longer at any step if side effects warrant a slower pace. There is no clinical benefit to skipping dose levels, escalating faster than four weeks, or going above 15mg weekly — faster titration produces worse nausea, not faster weight loss.

Why You Start So Low: The Logic of Slow Titration

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two gut-hormone receptors simultaneously. That dual mechanism is part of why tirzepatide produces larger weight loss than single-receptor GLP-1 medications — in the SURMOUNT-5 head-to-head trial, tirzepatide produced roughly 20.2% mean body-weight loss versus 13.7% for semaglutide at maximum tolerated doses over 72 weeks. But it is also why your digestive system needs time to adapt. The 2.5mg starting dose is explicitly an initiation dose, not a treatment dose — the FDA label states it is for treatment initiation only. Its job is to introduce tirzepatide gradually so that nausea, diarrhea, vomiting, and abdominal pain stay manageable while the gut adjusts. Most patients lose little weight at 2.5mg, and that is by design. Each subsequent step (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg) introduces a roughly 100% relative increase in hormone-receptor activation early in the ladder, and the four-week minimum interval gives the GI tract time to downregulate the symptomatic response before the next escalation. Pushing the schedule faster does not yield faster weight loss in any published trial; it just shifts more nausea into the same time window.

Tirzepatide Oral vs Injection — Two Different Dosing Schedules

The standard 2.5mg–15mg weekly schedule above describes injectable tirzepatide. Compounded oral tirzepatide follows a different ladder because daily dosing requires a different milligram range to achieve comparable receptor coverage. The PlexusDx Tirzepatide Oral Protocol covers seven dose levels from 5mg to 25mg taken daily ($279/mo), with the prescribing clinician selecting the starting dose and titration pace based on intake review. The injection format ($249/mo across six weekly dose levels from 2.5mg to 15mg) follows the FDA-aligned weekly schedule. Most patients who can self-inject and prefer once-weekly dosing choose the injection protocol; patients who are needle-averse, traveling frequently, or simply prefer a daily routine often choose the oral protocol. Neither format is more effective than the other when titrated to a comparable plasma exposure — the choice is about adherence fit, not pharmacology. If you are not sure which format suits you, the intake clinician on either protocol can help you decide; switching formats later is also possible if the first choice does not fit. Both protocols use compounded tirzepatide from licensed U.S. compounding pharmacies and are not FDA-approved finished drugs.

Compounded vs Brand-Name Tirzepatide — What Changes With Dosing

Brand-name tirzepatide (Zepbound and Mounjaro, manufactured by Eli Lilly) is dispensed in single-dose pens, single-dose vials, multi-dose KwikPens, and multi-dose vials at fixed dose strengths of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. The dose is engineered into the device — you do not measure anything; you inject the pen. Compounded tirzepatide (the format used by PlexusDx and most cash-pay platforms) is dispensed in multi-dose vials at varying concentrations — typically 10 mg/mL, 20 mg/mL, or 30 mg/mL — and you draw the prescribed dose with an insulin syringe. Concentration matters because the same syringe-unit reading converts to a different milligram dose at each concentration. At 10 mg/mL, 25 units equals 2.5mg. At 20 mg/mL, 25 units equals 5mg. At 30 mg/mL, 25 units equals 7.5mg. There is no universal units chart — you must check the concentration printed on your specific vial and confirm the conversion with your prescribing clinician or pharmacist before each draw. The PlexusDx Tirzepatide Injection protocol provides the concentration and the unit-to-milligram conversion for your specific prescription as part of the dose instructions, which removes the most common compounded-dosing error.

Genetics and Titration Pace — Why GIPR rs1800437 Matters

The standard four-weeks-per-step schedule is a population average. Individual response varies meaningfully — some patients tolerate 5mg with no GI symptoms and could move to 7.5mg in three weeks; others struggle with 2.5mg and need eight weeks before the next step. One of the genetic variables driving that variance is GIPR rs1800437, a coding variant in the GIP receptor (the GIP half of tirzepatide’s dual mechanism). GIPR rs1800437 has been associated in published research with differential GIP-axis signaling and, by extension, with altered response to GIP/GLP-1 dual agonists. The Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month on any PlexusDx protocol) reports your GIPR rs1800437 genotype alongside 56 other variants across 14 health pathways and 34 weight-management insights. The prescribing clinician on the PlexusDx Tirzepatide Injection Protocol reviews that result before dose decisions, which means the titration pace you start on is informed by your biology rather than a pure population default. Neither MEDVi, Ro, nor branded Lilly Direct performs this step before titration. PlexusDx is the only protocol in this comparison that anchors the titration ladder to a measurable genetic baseline.

Missed Doses, Day Changes, and Practical Schedule Mechanics

Tirzepatide has a half-life of approximately five days, which is why once-weekly dosing covers the full interval. If you miss a dose and remember within four days (96 hours) of your scheduled day, take it as soon as you remember and resume your normal schedule the following week. If more than four days have passed, skip the missed dose entirely and take your next dose on your regular day — never double up to compensate. To change your injection day, allow at least 72 hours (three days) between your last dose and the new dose; once you have done that, your new day becomes your weekly schedule going forward. Tirzepatide can be taken with or without food and at any time of day. It does not directly interact with alcohol, but alcohol can worsen GI side effects and is best limited during the first four to eight weeks of any escalation. Vials and pens require refrigeration (36°F to 46°F / 2°C to 8°C); for travel, an insulated cool pack is sufficient for short trips, and most products tolerate up to 30 days at room temperature below 86°F if refrigeration is unavailable — check your specific product label for the exact unrefrigerated allowance.

Side Effects by Dose Level — What to Expect at Each Step

Side-effect intensity tends to spike in the first one to two weeks after each dose increase, then fade as the gut adapts. The most common side effects across the full dose range are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and decreased appetite (which is partly the therapeutic effect). At 2.5mg, side effects are typically mild — this is the gentlest step. At 5mg through 10mg, GI symptoms are most pronounced for one to two weeks after each escalation, then subside. At 12.5mg and 15mg, baseline tolerability tends to be similar to 10mg for most patients who have already titrated through the lower steps. Less common but documented adverse effects include pancreatitis, gallbladder disease, acute kidney injury (often secondary to dehydration from GI symptoms), and hypersensitivity reactions. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies; the same boxed warning applies to semaglutide. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. If GI side effects become severe at any step, the appropriate response is to hold the current dose longer or step back — not to push through. The PlexusDx Tirzepatide Injection Protocol clinician adjusts pace based on your reported symptoms; you are not locked into a four-week-per-step march.

When NOT to Increase Your Tirzepatide Dose

The four-week interval is a minimum, not a target. Several scenarios warrant holding at your current dose rather than escalating: persistent moderate-to-severe nausea or vomiting, signs of dehydration, ongoing weight loss at the current dose (if it is still working, do not change it), pregnancy or planning pregnancy (tirzepatide is contraindicated), new gallbladder symptoms, severe abdominal pain that could indicate pancreatitis, or any change in kidney function. Patients on insulin or sulfonylureas may need those medications dose-reduced before tirzepatide titration to prevent hypoglycemia. The maximum approved weekly dose for adults is 15mg — going above is not supported by trial data and increases risk without measurable benefit. If you have plateaued at 15mg and are still seeking further weight loss, the conversation shifts from dose escalation to combination therapy, behavioral support, or evaluating whether the current weight is your sustainable maintenance point. The PlexusDx GLP-Squared Protocol ($249/mo) offers a dual-compound semaglutide-plus-tirzepatide pathway for patients who have already optimized monotherapy and are working with their clinician on next-step options.

Frequently asked questions

What is the standard tirzepatide dosing schedule?

The standard FDA tirzepatide titration is 2.5mg weekly for four weeks, then 5mg weekly for four weeks, then escalation by 2.5mg every four or more weeks through 7.5mg, 10mg, 12.5mg, and a maximum of 15mg weekly. The PlexusDx Tirzepatide Injection Protocol follows this same six-step ladder using compounded tirzepatide.

How long do you stay on 2.5mg of tirzepatide?

A minimum of four weeks. Some patients stay on 2.5mg longer if side effects are persistent at that dose, but most move to 5mg at the four-week mark. The 2.5mg dose is an initiation step, not a treatment dose.

What is the maximum dose of tirzepatide?

15mg once weekly for adults across all approved indications. Going above 15mg is not supported by clinical trial data and is not recommended. The PlexusDx Tirzepatide Injection Protocol covers all six dose levels up to 15mg weekly.

What does 25 units of tirzepatide equal in milligrams?

It depends on the concentration of your compounded vial. At 10 mg/mL concentration, 25 units equals 2.5mg. At 20 mg/mL, 25 units equals 5mg. At 30 mg/mL, 25 units equals 7.5mg. Always check your vial label and confirm the conversion with your prescribing clinician before drawing a dose.

What if I miss a dose of tirzepatide?

If less than four days (96 hours) have passed since your scheduled dose, take it as soon as you remember and continue your normal weekly schedule. If more than four days have passed, skip the missed dose and take your next dose on your regular day. Never double up.

How is the tirzepatide oral dosing schedule different from the injection schedule?

Compounded oral tirzepatide is taken daily rather than weekly. The PlexusDx Tirzepatide Oral Protocol covers seven dose levels from 5mg to 25mg daily, with titration pace selected by the prescribing clinician. The injection protocol covers six weekly dose levels from 2.5mg to 15mg.

Can genetic testing change my tirzepatide titration pace?

Yes, in the sense that the prescribing clinician uses the result to inform pace and starting dose selection. The PlexusDx Precision Peptide Genetic Test reports your GIPR rs1800437 genotype, a variant associated with differential response to GIP/GLP-1 dual agonists, alongside 56 other variants. The result is reviewed before titration decisions on the Tirzepatide Injection Protocol; the test is $298 standalone or $99 as an add-on after your first month.

Tirzepatide Dosing Schedule (2026): Week-by-Week Titration Chart | PlexusDx